Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and TT11 (CD30.CAR-T) in r/r cHL
NCT05352828Phase 1Active, not recruiting
- Sponsor
- Tessa Therapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD30.CAR-T in classical Hodgkin lymphoma (cHL), sponsored by Tessa Therapeutics. Primary endpoint: Safety of autologous CD30.CAR-T in combination with nivolumab. Started Jul 2022; status: active, not recruiting.
02
Drugs
autologous CD30.CAR-T
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05352828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352828.